Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling

Human Molecular Genetics

Volumn 23, Issue 5, 2014, Pages 1237-1249

  Acuña, María José ^a   Pessina, Patrizia ^b   Olguin, Hugo ^a   Cabrera, Daniel ^a   Vio, Carlos P ^a   Bader, Michael ^c   Muñoz canoves, Pura ^b   Santos, Robson A ^d   Cabello verrugio, Claudio ^a   Brandan, Enrique ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANIMALS; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; MALE; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MICRORNAS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84894049100     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt514     Document Type: Article

References (58)

1. Matsumura, K. and Campbell, K.P. (1994) Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve, 17, 2-15.
2. Blake, D.J., Weir, A., Newey, S.E. and Davies, K.E. (2002) Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82, 291-329.
3. Mann, C.J., Perdiguero, E., Kharraz, Y., Aguilar, S., Pessina, P., Serrano, A.L. and Munoz-Canoves, P. (2011) Aberrant repair and fibrosis development in skeletal muscle. Skeletal Muscle, 1, 21.
4. Serrano, A.L. and Munoz-Canoves, P. (2010) Regulation and dysregulation of fibrosis in skeletal muscle. Exp. Cell Res., 316, 3050-3058.
5. Caceres, S., Cuellar, C., Casar, J.C., Garrido, J., Schaefer, L., Kresse, H. and Brandan, E. (2000) Synthesis of proteoglycans is augmented in dystrophic mdx mouse skeletal muscle. Eur. J. Cell Biol., 79, 173-181.
6. Wynn, T.A. (2008) Cellular and molecular mechanisms of fibrosis. J. Pathol., 214, 199-210.
7. Wynn, T.A. (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J. Clin. Invest., 117, 524-529.
8. Marangoni, R.A., Carmona, A.K., Passaglia, R.C., Nigro, D., Fortes, Z.B. and de Carvalho, M.H. (2006) Role of the kallikrein-kinin system in Ang-(1-7)-induced vasodilation in mesenteric arterioles of Wistar rats studied in vivo-in situ. Peptides, 27, 1770-1775.
9. Ferrario, C.M., Trask, A.J. and Jessup, J.A. (2005) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am. J. Physiol. Heart Circ. Physiol., 289, H2281-H2290.
10. Tallant, E.A., Ferrario, C.M. and Gallagher, P.E. (2005) Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Cir. Physiol., 289, H1560-H1566.
11. Iwata, M., Cowling, R.T., Gurantz, D., Moore, C., Zhang, S., Yuan, J.X. and Greenberg, B.H. (2005) Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol., 289, H2356-H2363.
12. Grobe, J.L., Mecca, A.P., Lingis, M., Shenoy, V., Bolton, T.A., Machado, J.M., Speth, R.C., Raizada, M.K. and Katovich, M.J. (2007) Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am. J. Physiol. Heart Cir. Physiol., 292, H736-H742.
13. Benter, I.F., Ferrario, C.M., Morris, M. and Diz, D.I. (1995) Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am. J. Physiol., 269, H313-H319.
14. Ferreira, A.J., Santos, R.A. and Almeida, A.P. (2001) Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension, 38, 665-668.
15. Santos, R.A., Simoes e Silva, A.C., Maric, C., Silva, D.M.,Machado, R.P., de Buhr, I., Heringer-Walther, S., Pinheiro, S.V., Lopes, M.T., Bader, M. et al. (2003) Angiotensin-(1-7) is an endogenous ligand for theGprotein-coupled receptor Mas. Proc. Natl Acad. Sci. USA, 100, 8258-8263.
16. Warner, F.J., Lubel, J.S., McCaughan, G.W. and Angus, P.W. (2007) Liver fibrosis: a balance of ACEs? Clin. Sci. (Lond.), 113, 109-118.
17. Prud'homme, G.J. (2007) Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Invest., 87, 1077-1091.
18. Vial, C., Zuniga, L.M., Cabello-Verrugio, C., Canon, P., Fadic, R. and Brandan, E. (2008) Skeletal muscle cells express the profibrotic cytokine connective tissue growth factor (CTGF/CCN2), which induces their dedifferentiation. J. Cell. Physiol. 215, 410-421.
19. Massague, J. (2000) How cells read TGF-beta signals. Nat. Rev. Mol. Cell. Biol., 1, 169-178.
20. Cohn, R.D., van Erp, C., Habashi, J.P., Soleimani, A.A., Klein, E.C., Lisi, M.T., Gamradt, M., ap Rhys, C.M., Holm, T.M., Loeys, B.L. et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med., 13, 204- 210.
21. Burks, T.N., Andres-Mateos, E., Marx, R., Mejias, R.,VanErp, C., Simmers, J.L., Walston, J.D., Ward, C.W. and Cohn, R.D. (2011) Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Trans. Med., 3, 82ra37.
22. Cabello-Verrugio, C., Santander, C., Cofre, C., Acuna, M.J., Melo, F. and Brandan, E. (2012) The internal region leucine-rich repeat 6 of decorin interacts with low density lipoprotein receptor-related protein-1, modulates transforming growth factor (TGF)-beta-dependent signaling, and inhibits TGF-beta-dependent fibrotic response in skeletal muscles. J. Biol. Chem., 287, 6773-6787.
23. Pierno, S., Nico, B., Burdi, R., Liantonio, A., Didonna, M.P., Cippone, V., Fraysse, B., Rolland, J.F., Mangieri, D., Andreetta, F. et al. (2007) Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol. Appl. Neurobiol., 33, 344-359.
24. Beggs, M.L., Nagarajan, R., Taylor-Jones, J.M., Nolen, G., Macnicol, M. and Peterson, C.A. (2004) Alterations in the TGFbeta signaling pathway in myogenic progenitors with age. Aging cell., 3, 353-361.
25. Pastoret, C. and Sebille, A. (1995) Mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci., 129, 97-105.
26. Marques, F.D., Ferreira, A.J., Sinisterra, R.D., Jacoby, B.A., Sousa, F.B., Caliari, M.V., Silva, G.A., Melo, M.B., Nadu, A.P., Souza, L.E. et al. (2011) An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension, 57, 477-483.
27. Santos, R.A., Campagnole-Santos, M.J., Baracho, N.C., Fontes, M.A., Silva, L.C., Neves, L.A., Oliveira, D.R., Caligiorne, S.M., Rodrigues, A.R., Gropen Junior, C. et al. (1994) Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res. Bull., 35, 293-298.
28. Ardite, E., Perdiguero, E., Vidal, B., Gutarra, S., Serrano, A.L. and Munoz-Canoves, P. (2012) PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J. Cell Biol., 196, 163-175.
29. Mathew, S.J., Hansen, J.M., Merrell, A.J., Murphy, M.M., Lawson, J.A., Hutcheson, D.A., Hansen, M.S., Angus-Hill, M. and Kardon, G. (2011) Connective tissue fibroblasts and Tcf4 regulate myogenesis. Development, 138, 371-384.
30. Pereira, R.M., dos Santos, R.A., da Costa Dias, F.L., Teixeira, M.M. and Simoes e Silva, A.C. (2009) Renin-angiotensin system in the pathogenesis of liver fibrosis. World J. Gastroenterol., 15, 2579-2586.
31. Iwai, M. and Horiuchi, M. (2009) Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens. Res., 32, 533-536.
32. Santos, R.A., Ferreira, A.J., Verano-Braga, T. and Bader, M. (2013) Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol., 216, R1-R17.
33. Fraga-Silva, R.A., Da Silva, D.G., Montecucco, F., Mach, F., Stergiopulos, N., da Silva, R.F. and Santos, R.A. (2012) The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb. Haemostasis., 108, 1089-1096.
34. Bader, M., Santos, R.A., Unger, T. and Steckelings, U.M. (2012) New therapeutic pathways in the RAS. J. Ren. Ang. Aldost. Syst., 13, 505-508.
35. Melo, F., Carey, D.J. and Brandan, E. (1996) Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression. J. Cell Biochem., 62, 227-239.
36. Osses, N. and Brandan, E. (2002) ECM is required for skeletal muscle differentiation independently of muscle regulatory factor expression. Am. J. Physiol. Cell Physiol., 282, C383-C394.
37. Fadic, R. (2005) Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne. Biol. Res., 38, 375-380.
38. Cohn, R.D., Mayer, U., Saher, G., Herrmann, R., van der Flier, A., Sonnenberg, A., Sorokin, L. and Voit, T. (1999) Secondary reduction of alpha7B integrin in laminin alpha2 deficient congenital muscular dystrophy supports an additionaltransmembrane link in skeletal muscle. J. Neurol. Sci., 163, 140-152.
39. Cornelison, D., Filla, M., Stanley, H., Rapraeger, A. and Olwin, B. (2001) Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration. Dev. Biol., 239, 79-94.
40. Cornelison, D.D., Wilcox-Adelman, S.A., Goetinck, P.F., Rauvala, H., Rapraeger, A.C. and Olwin, B.B. (2004) Essential and separable roles for Syndecan-3 and Syndecan-4 in skeletal muscle development and regeneration. Genes Dev., 18, 2231-2236.
41. Casar, J.C., Cabello-Verrugio, C., Olguin, H., Aldunate, R., Inestrosa, N.C. and Brandan, E. (2004) Heparan sulfate proteoglycans are increased during skeletal muscle regeneration: requirement of syndecan-3 for successful fiber formation. J. Cell Sci., 117, 73-84.
42. Gutierrez, J. and Brandan, E. (2010) A novel mechanism of sequestering fibroblast growth factor 2 by glypican in lipid rafts, allowing skeletal muscle differentiation. Mol. Cell. Biol., 30, 1634-1649.
43. Burks, T.N. and Cohn, R.D. (2011) Role of TGF-beta signaling in inherited and acquired myopathies. Skeletal Muscle, 1, 19.
44. Kollias, H.D. and McDermott, J.C. (2008) Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol., 104, 579-587.
45. Chen, Y.W., Nagaraju, K., Bakay, M., McIntyre, O., Rawat, R., Shi, R. and Hoffman, E.P. (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology, 65, 826-834.
46. Zhou, L. and Lu, H. (2010) Targeting fibrosis in Duchenne muscular dystrophy. J. Neuropathol. Exp. Neurol., 69, 771-776.
47. Elbaz, M., Yanay, N., Aga-Mizrachi, S., Brunschwig, Z., Kassis, I., Ettinger, K., Barak, V. and Nevo, Y. (2012) Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J) /dy(2J) mouse. Ann. Neurol., 71, 699-708.
48. Bernasconi, P., Di Blasi, C., Mora, M., Morandi, L., Galbiati, S., Confalonieri, P., Cornelio, F. and Mantegazza, R. (1999) Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscular Disord., 9, 28-33.
49. Ferrario, C.M. (2011) ACE2: more of Ang-(1-7) or less Ang II? Curr. Opin. Nephrol. Hypertens., 20, 1-6.
50. Zhou, L., Wang, L., Lu, L., Jiang, P., Sun, H. and Wang, H. (2012) Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts. PLoS One, 7, e33766.
51. Wang, L., Zhou, L., Jiang, P., Lu, L., Chen, X., Lan, H., Guttridge, D.C., Sun, H. and Wang, H. (2012) Loss of miR-29 in myoblasts contributes to dystrophic muscle pathogenesis. Mol. Ther., 20, 1222-1233.
52. Serrano, A.L., Mann, C.J., Vidal, B., Ardite, E., Perdiguero, E. and Munoz-Canoves, P. (2011) Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr. Top. Dev. Biol., 96, 167-201.
53. Walther, T., Balschun, D., Voigt, J.P., Fink, H., Zuschratter, W., Birchmeier, C., Ganten, D. and Bader, M. (1998) Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J. Biol. Chem., 273, 11867-11873.
54. De Luca, A., Nico, B., Liantonio, A., Didonna, M.P., Fraysse, B., Pierno, S., Burdi, R., Mangieri, D., Rolland, J.F., Camerino, C. et al. (2005) A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. Am. J. Pathol., 166, 477-489.
55. Morales, M.G., Gutierrez, J., Cabello-Verrugio, C., Cabrera, D., Lipson, K.E., Goldschmeding, R. and Brandan, E. (2013) Hum. Mol. Genet., 22, 4938-4951.
56. Morales, G., Cabello-Verrugio, C., Cabrera, D., Goldschmeding, R. and Brandan, E. (2011) CTGF/CCN-2 overexpression can directly induce features of skeletal muscle dystrophy. J. Pathol., 225, 490-501.
57. Li, Y., Foster, W., Deasy, B.M., Chan, Y., Prisk, V., Tang, Y., Cummins, J. and Huard, J. (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am. J. Pathol., 164, 1007-1019.
58. Silahtaroglu, A.N., Nolting, D., Dyrskjot, L., Berezikov, E., Moller, M., Tommerup,N. and Kauppinen, S. (2007) Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat. Protoc., 2, 2520-2528.